Updates are available Correction dated 2024-03-18
Click to view Correction: https://doi.org/10.1007/s00415-024-12249-9
-
Authors
Abdelgaied, Mohamed Y.
Rashad, Mohamed Hamed
El-Tayebi, Hend M.
Solayman, Mohamed H. http://orcid.org/0009-0008-3723-1052
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05298670 at ClinicalTrials.govDocuments that mention this clinical trial
The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial
https://doi.org/10.1007/s00415-023-12113-2
- License Information
-
More Information
Article History
Received: 30 July 2023
Revised: 9 November 2023
Accepted: 10 November 2023
First Online: 9 December 2023
Change Date: 18 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00415-024-12249-9
Declarations
:
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: The Research Ethics Committee at the Egyptian Ministry of Health approved and registered the study protocol (Com.No/Dec.No: 8-2022/5). This study was conducted according to the 1964 Declaration of Helsinki and its later amendments. All patients were educated about the study protocol and were required to sign a written informed consent before participation without any obligation to complete the study. The study was registered at “Clinical-Trials.gov” with identifier number: NCT05298670.
